On November 19, 2025 TriOar reported that it has signed a technology transfer and co-development conversion rights agreement with Celltrion for its platform technology, ‘ TRACAD ( TriOar’s Conditionally Activatable Domain )’. The scale of the contract is a total of $356 million (approx. 522 billion won) if all licenses for six targets are exercised, including development milestones of up to $231 million (approx. 338 billion won) and sales milestones of up to $125 million (approx. 183 billion won).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Triore is a biotech company in the ADC sector. In short, ADCs are next-generation anticancer drugs that deliver drugs directly using a guided missile-like mechanism. They consist of a structure in which an antibody that binds to cancer antigens is combined with a cytotoxic drug (payload) capable of killing cancer cells via a linker . Because the antibody guides the drug to cancer cells and attacks them selectively, it targets only cancer cells rather than normal cells. Compared to conventional chemotherapy, this approach enhances efficacy, reduces drug toxicity, and minimizes damage to normal tissues. TROCAD, Triore’s core platform technology , is designed to ensure drugs reach cancer tissue more accurately while blocking unnecessary binding to normal cells. It maximizes drug delivery efficiency to cancer lesions while reducing toxicity by blocking binding to normal cells.
Celltrion can apply the technology to the development and commercialization of up to six ADCs . The agreement also includes an option to switch to joint development for two of these targets. If Celltrion exercises this option, the two companies will share additional ADC application technologies and know-how.
Triore emphasized, "This agreement is considered recognition of the competitiveness of our platform technology in the global market," adding, "Both companies plan to expand cooperation in new drug development based on this technology in the future."
(Press release, TriOar Biotechnology, NOV 19, 2025, View Source;idx=13 [SID1234664837])